We sought to determine the real-world effectiveness of respiratory syncytial virus (RSV) immunoprophylaxis in a population-based cohort to inform policy. The study population included infants born during 1996-2008 and enrolled in the Kaiser Permanente Northern California integrated health-care delivery system. During the RSV season (November-March), the date of RSV immunoprophylaxis administration and the following 30 days were defined as RSV immunoprophylaxis protected period(s), and all other days were defined as unprotected period(s). Numbers of bronchiolitis hospitalizations were determined using International Classification of Diseases, Ninth Revision, codes during RSV season. We used a proportional hazards model to estimate risk of bronchiolitis hospitalization when comparing infants' protected period(s) with unprotected period(s). Infants who had ever received RSV immunoprophylaxis had a 32% decreased risk of bronchiolitis hospitalization (adjusted hazard ratio = 0.68, 95% confidence interval: 0.46, 1.00) when protected periods were compared with unprotected periods. Infants with chronic lung disease (CLD) had a 52% decreased risk of bronchiolitis hospitalization (adjusted hazard ratio = 0.48, 95% confidence interval: 0.25, 0.94) when protected periods were compared with unprotected periods. Under the new 2014 American Academy of Pediatrics (AAP) guidelines, 48% of infants eligible for RSV immunoprophylaxis on the basis of AAP guidelines in place at birth would no longer be eligible, but nearly all infants with CLD would remain eligible. RSV immunoprophylaxis is effective in decreasing hospitalization. This association is greatest for infants with CLD, a group still recommended for receipt of RSV immunoprophylaxis under the new AAP guidelines. bronchiolitis; bronchiolitis hospitalization; high-risk infants; immunoprophylaxis; infancy; lower respiratory tract infection; respiratory syncytial virus Abbreviations: AAP, American Academy of Pediatrics; aHR, adjusted hazard ratio; CI, confidence interval; CLD, chronic lung disease; IRR, incidence rate ratio; KPNC, Kaiser Permanente Northern California; RCT, randomized clinical trial; RSV, respiratory syncytial virus.
Respiratory syncytial virus (RSV) infection is the leading cause of viral lower respiratory tract infections, such as bronchiolitis, in infants and young children (1) (2) (3) . No effective treatment for RSV exists, nor is there an efficacious RSV vaccine yet available for the prevention of serious RSV infection. The only available pharmacological preventive strategy for severe RSV infection is the administration of an RSV monoclonal antibody licensed for use in high-risk infants (4, 5) .
Randomized clinical trials (RCTs) have demonstrated that passive RSV immunoprophylaxis is efficacious in reducing RSVrelated hospitalizations in infants who are at increased risk for RSV infection (6) (7) (8) (9) . The US Food and Drug Administration first approved the use of RSV immunoprophylaxis in 1996 (10) , and the American Academy of Pediatrics (AAP) issued recommendations for RSV immunoprophylaxis for selected high-risk infants in 1997 (4), with subsequent updates (5, (11) (12) (13) (14) . Guidelines regarding eligibility for, and timing of receipt of, RSV immunoprophylaxis have changed over time; it has been recommended that infants with chronic lung disease (CLD), congenital heart disease, and premature birth receive immunoprophylaxis during the winter RSV season of their first year of life (5, 11, 13) . The AAP updated its guidelines in 2009 (12) and 2014 (5) with modified infant eligibility. The proportion of infants impacted and the realworld effectiveness across eligibility groups are not known.
While RCTs have established efficacy, what is needed to further inform policy on this costly preventive therapy is current real-world effectiveness studies of immunoprophylaxis. The likelihood of administration and timing of receipt of immunoprophylaxis, even among recommended high-risk infants, varies based upon the infants' risk for RSV infection, which depends on the severity and timing of the actual RSV seasons (15) . Additionally, CLD of prematurity has significantly changed since the efficacy studies were conducted (16, 17) . Our objective in this study was to obtain data needed for policy and clinical-care decisions by assessing the effectiveness of RSV immunoprophylaxis in reducing numbers of bronchiolitis hospitalizations among infants who were eligible and/or received RSV immunoprophylaxis, as well as to examine the proportion of infants likely to be affected by the new 2014 guidelines (5) . Critical to such analyses of observational data is the application of methods of adjustment for treatment indication bias, the duration of effect of immunoprophylaxis, and the temporal relationship between receipt of RSV immunoprophylaxis, bronchiolitis hospitalizations, and the epidemic circulation and risk of RSV infection.
METHODS

Study population
A cohort of 211,098 infants born between 1996 and 2008 and continuously enrolled during the first year of life in Kaiser Permanente Northern California (KPNC), an integrated health-care delivery system, were included ( Figure 1 ) (15) . We categorized infants into 5 mutually exclusive and hierarchical eligibility groups based on the in-place AAP guidelines recommended during our study period, as described previously: 1) CLD that required medical therapy in the 6 months preceding the RSV season; 2) prematurity of <29 completed weeks' gestation; 3) prematurity of 29-31 weeks' gestation; 4) other eligibility (e.g., 32-to 34-week infants with 2 or more risk factors, infants with congenital heart disease, etc.); and 5) ineligible for RSV immunoprophylaxis. Infants in groups 1-4 were considered eligible for RSV immunoprophylaxis based on the literature and guidelines (5, 11, 13) . The study protocol was approved by the KPNC and Vanderbilt University institutional review boards and the State of California Committee for the Protection of Human Subjects.
RSV season, immunoprophylaxis receipt, and protected/ unprotected periods
We defined RSV season as November-March in order to capture RSV-specific morbidity by minimizing misclassification of events caused by viruses other than RSV, which is also consistent with the AAP-defined season for receipt of RSV immunoprophylaxis for most US areas, including California (5). We captured data on administration of RSV immunoprophylaxis using a pharmacy database that included information on outpatient visits, medications, and the dates of immunoprophylaxis administration (see Web Figure 1A , available at https://academic.oup. com/aje). RSV immunoprophylaxis is efficacious for eligible infants during the RSV season, and dosing is recommended every 30 days for such infants (5, 18) . We defined the 30-day interval following administration of RSV immunoprophylaxis as the protected period. All days during the RSV season that did not fall within a protected period were defined as the unprotected period ( Figure 2 and Web Figure 2 ). We distinguished and identified 2 different types of unprotected periods. One was the unprotected period for infants who never received any RSV immunoprophylaxis; the other was the unprotected period for those infants who received at least 1 dose of immunoprophylaxis but did not receive it every 30 days.
Bronchiolitis hospitalizations
Numbers of bronchiolitis hospitalizations during the 5-month RSV season of each infant's first 12 months of life were captured using International Classification of Diseases, Ninth Revision, codes (466.1 and 480.1) for bronchiolitis (Web Figure 1B) . Our definition of bronchiolitis hospitalization has been validated previously (19) (20) (21) .
Statistical analysis
We expressed descriptive statistics as proportions for categorical variables and as means and standard deviations or medians and interquartile ranges for continuous variables, as appropriate.
We assessed the effectiveness of RSV immunoprophylaxis by comparing bronchiolitis hospitalization incidence rates between protected and unprotected periods. The incidence rate ratio was estimated within eligibility groups, as well as among infants who received at least 1 dose of immunoprophylaxis.
We limited the estimation of effectiveness of RSV immunoprophylaxis to the 3,210 infants who received at least 1 dose of immunoprophylaxis. A Cox proportional hazards regression model with repeated measures was fitted adjusting for both fixed and timedependent covariates (22) . Type of immunoprophylaxis period (protected or unprotected) was considered as a time-dependent variable. Similar models were developed for each eligibility group. Detailed information on the regression models can be found in the Web Appendix. Additional sensitivity analyses regarding the 30-day protection window were conducted (Web Appendix, Web Figure 3 ).
Two types of RSV immunoprophylaxis, RSV immune globulin intravenous (licensed in 1996) and palivizumab (licensed in 1998), were available during the study period. KPNC administered palivizumab almost exclusively starting in 1998. We conducted a subgroup analysis of children born in 1998 and afterwards to determine the palivizumab-specific association with bronchiolitis hospitalization.
The AAP subsequently updated its guidelines for RSV immunoprophylaxis in 2009 (12) and 2014 (5), modifying the criteria for infant eligibility and the number of doses an eligible infant should receive. We estimated the proportions of infants who were eligible and ineligible under the old and new guidelines and the effectiveness of immunoprophylaxis in the 2 subgroups.
All analyses were performed using R software, version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria; www. r-project.org), and SAS software, version 9.3 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
Receipt of RSV immunoprophylaxis
There were 211,098 infants born and enrolled in the cohort over the 13-year study period (1996-2008) ( Table 1) . Among those infants, 3,444 (1.63%) were eligible for RSV immunoprophylaxis based on the guidelines in place at birth, and 3,210 infants (1.52%) received at least 1 dose. Infants in the CLD and <29-weeks'-gestation eligibility groups were the most likely to receive immunoprophylaxis (76.5% and 78.6%, respectively), while infants in the "other" eligibility group were the least likely to receive it (15.6%) ( Table 1 ). Among infants who ever received immunoprophylaxis, the median number of doses received was 4 (interquartile range, [3] [4] [5] .
Across all eligibility groups, higher-risk infants were more likely to receive RSV immunoprophylaxis ( Table 2 and Web  Table 1 ). Compared with infants who did not receive any immunoprophylaxis, infants who received at least 1 dose were more likely to be male and to have a lower gestational age, a lower birth weight, a longer birth hospitalization length of stay, other siblings at home, mothers who smoked during pregnancy, and less educated mothers (P < 0.01). Infants who received at least 1 dose were also more likely to have congenital heart disease or a neuromuscular disorder than infants who did not receive any immunoprophylaxis.
Effectiveness of RSV immunoprophylaxis
The effectiveness of RSV immunoprophylaxis was studied among infants who were either eligible based on AAP guidelines or received at least 1 dose of immunoprophylaxis (Table 3) . Compared with eligible infants who never received immunoprophylaxis, infants who received at least 1 dose had an increased risk of bronchiolitis hospitalization during the unprotected periods (incidence rate ratio (IRR) = 1.49, 95% confidence interval (CI): 1.00, 2.24) but not during the protected periods (IRR = 0.97, 95% CI: 0.68, 1.39). These results were consistent when we limited the analysis to eligible-only infant groups. Such results were most likely due to indication bias in which infants at higher risk for infection were more likely to receive immunoprophylaxis. This was also evident in the subgroup of ineligible infants, where receipt of immunoprophylaxis significantly increased the risk of bronchiolitis hospitalization in both protected and unprotected periods compared with infants who never received immunoprophylaxis.
The adjusted analysis was then limited to infants who received at least 1 dose of RSV immunoprophylaxis, as we had previously recognized bias for receipt of immunoprophylaxis in a prior study The start of follow-up was the first day on which infants were eligible for RSV immunoprophylaxis based on American Academy of Pediatrics guidelines, the first day after birth hospitalization discharge, or the start of the RSV season (November 1), whichever came last. The end of follow-up was the last day on which infants were eligible for RSV immunoprophylaxis, the infant's first birthday, or the end of the RSV season (March 31), whichever came first. Circles denote bronchiolitis hospitalization, and diamonds denote administration of RSV immunoprophylaxis. with inability to adequately adjust for differential propensity for prescribing (15, 23) . Among infants who received any RSV immunoprophylaxis, receipt of immunoprophylaxis decreased the risk of bronchiolitis hospitalization during protected periods as compared with unprotected periods (IRR = 0.65, 95% CI: 0.46, 0.93). This protective association was consistent after adjustment for covariates (adjusted hazard ratio (aHR) = 0.68, 95% CI: 0.46, 1.00) ( Table 4) . Prior receipt of immunoprophylaxis in the same season was associated with a decreased risk of bronchiolitis hospitalization after controlling for the 30-day protected periods after administration (aHR = 0.49, 95% CI: 0.28, 0.88). We further estimated the effectiveness of immunoprophylaxis in each eligibility group (Tables 3 and 4) . Infants in the CLD eligibility group had the largest risk reduction during the protected period(s), with a risk of bronchiolitis hospitalization that was decreased by 57% (IRR = 0.43, 95% CI: 0.23, 0.81) in the unadjusted analysis and by 52% after adjustment for covariates (aHR = 0.48, 95% CI: 0.25, 0.94). Among infants in the ineligible but treated group (who nevertheless received at least some immunoprophylaxis), the risks in the protected periods were decreased by 47% (IRR = 0.53, 95% CI: 0.30, 0.93) and 49% (aHR = 0.51, 95% CI: 0.30, 0.86), respectively. There was no similar significantly decreased risk of bronchiolitis hospitalization with RSV immunoprophylaxis in the 2 premature eligibility groups or the "other" eligibility group (Tables 3 and 4) .
In sensitivity analyses, results were unchanged when we extended the RSV immunoprophylaxis-protected time from 30 days to 35 days or when we delayed the starting time of the protective period to 4 days following administration (Web Tables 2-4 ). The association was consistent when we limited the analyses to infants born in 1998 and afterward, when infants almost exclusively received palivizumab (Web Tables 3 and 5) . Table 6 ). Among them, 75% (n = 1,332) received at least 1 dose of immunoprophylaxis, and 4% (n = 75) experienced at least 1 bronchiolitis hospitalization (Web Table 7 ). The risk of bronchiolitis hospitalization was nonsignificantly decreased (aHR = 0.94, 95% CI: 0.44, 2.03) among the infants who had ever received immunoprophylaxis.
Of the 1,661 infants (48%) who would no longer be eligible on the basis of the current guidelines, 56% (n = 929) received at least 1 dose of immunoprophylaxis, and 3% (n = 53) experienced 56 bronchiolitis hospitalizations in total (Web Tables 6 and 7) . Risk of bronchiolitis hospitalization was nonsignificantly decreased by 36% (aHR = 0.64, 95% CI: 0.29, 1.40) among infants who ever received immunoprophylaxis.
DISCUSSION
To our knowledge, this was the first population-based study of the effectiveness of RSV immunoprophylaxis in reducing infant bronchiolitis morbidity that accounted for indication IRRs were calculated within each eligibility group, among all eligible subjects, all subjects who ever received immunoprophylaxis, and infants who either were eligible or ever received immunoprophylaxis. Within each group, IRRs were calculated using either the unprotected periods of subjects who never received RSV immunoprophylaxis or the unprotected periods of subjects who ever received RSV immunoprophylaxis as the reference group.
f "Other eligible group" included infants who were born at 32-34 weeks of gestation with 2 or more additional risk factors and infants who had congenital heart disease.
bias, duration of effect of treatment, and the temporal relationship between treatment and outcome during the annual RSV epidemic and that assessed the impact of the updated 2009 and 2014 AAP guidelines for use of RSV immunoprophylaxis.
In this study population, infants who received at least 1 dose of RSV immunoprophylaxis had a 32% decrease in risk of bronchiolitis hospitalization within 30 days of administration, independent of prior immunoprophylaxis receipt. While the decreased risk associated with receipt of RSV immunoprophylaxis observed in this study was smaller than the 55% reduction reported in the RCTs of efficacy (9), reduced effectiveness in comparison with corresponding efficacy in RCTs is common, as real-world effectiveness studies often include different populations and decreased adherence (24) . Within one RSV season, prior receipt of any immunoprophylaxis was independently associated with a decreased risk of bronchiolitis hospitalization, even during unprotected periods. Thus, infants were less likely to experience a bronchiolitis hospitalization during the unprotected period if they had a preceding protected period/receipt of immunoprophylaxis. The smaller reduction in effectiveness as compared with efficacy may be due to the extended protection conferred by RSV immunoprophylaxis in a study comparing protected and unprotected periods, but it also may be due to the type of intervention, which requires in-person administration during pediatrician visits, resulting in high adherence and known receipt of drug in comparison with most real-world effectiveness studies. This result is consistent with previous findings that subsequent use (days 1-30 of each subsequent dose) and former use (days 31-60 after any dose if delays or no readministration occurred) significantly reduced the risk of RSVrelated hospitalization (25) . Our findings are also consistent with the elevated trough serum concentrations measured after the third and fourth monthly injections (26) .
CLD is one of the strongest known risk factors for severe RSV infection, and it was also a significant determinant of enhanced adherence to immunoprophylaxis in this study. Among infants with CLD, receipt of RSV immunoprophylaxis was associated with a 52% decrease in risk of bronchiolitis hospitalization. Such a significant reduction in risk of bronchiolitis hospitalization was supported by decreasing hospitalization rates in this population over the course of the study period as the proportion receiving immunoprophylaxis increased over time (Web Figure 4) (15) . It is noteworthy that rates of bronchiolitis hospitalization in infants with CLD who ever and never received immunoprophylaxis were 16% and 26%, respectively, which is a much higher rate than that observed in children with bronchopulmonary dysplasia enrolled in the IMpact-RSV Study (8% and 13% in the immunoprophylaxis and placebo groups, respectively) (9). The difference is likely due to an evolving definition, evolving diagnosis, and different pathophysiology of CLD/bronchopulmonary dysplasia as management has changed over time. Children defined as having CLD in our study were probably different from and a Infants included in these analyses received at least 1 dose of RSV immunoprophylaxis. b Cox proportional hazards models adjusted for both fixed and time-dependent covariates, including infant age at receipt of RSV immunoprophylaxis, prior receipt of RSV immunoprophylaxis (during the same RSV season), prior history of bronchiolitis hospitalization, infant birth weight (g), gestational age (in completed weeks), infant race/ethnicity, sex, infant birth season, length of birth hospitalization stay, number of living siblings, singleton birth, maternal age at delivery (in years), maternal education (in years), maternal smoking during pregnancy, and RSV immunoprophylaxis eligibility group. The RSV immunoprophylaxis-unprotected period served as the reference category for each eligibility group.
c Five infants were removed from multivariable analyses because of unknown sex (1 infant), missing race/ethnicity (2 infants), and missing number of living siblings (2 infants). The 5 infants removed did not experience any bronchiolitis hospitalizations during the 5-month follow-up time in infancy.
d "Other eligible group" included infants who were born at 32-34 weeks of gestation with 2 or more additional risk factors and infants who had congenital heart disease.
e HR and 95% CI were not calculated because of the limited number of events among subjects within-group.
sicker than children enrolled in previous studies (16, 17, 27) . Second, the higher rate observed in our study may in part be secondary to non-RSV pathogens. Nevertheless, the significant reduction we observed demonstrates that RSV immunoprophylaxis is effective in reducing bronchiolitis hospitalization in this population. Premature birth is another significant and known risk factor for severe RSV infection. Extreme prematurity (birth at <29 weeks) was also a significant determinant of enhanced adherence to immunoprophylaxis. However, there were no differences in the risks of bronchiolitis hospitalization between protected and unprotected periods in the subgroups of infants born at less than 29 completed weeks of gestation and between 29 and 31 weeks of gestation. The nonsignificant result is different from the 78% risk reduction reported in the IMpact-RSV Study (9) and might be due to the limited sample size and small number of bronchiolitis hospitalizations observed in our study. Compared with the 2% and 8% prevalences of RSV hospitalization observed in immunoprophylaxis-treated and placebo groups among premature infants enrolled in the RCT, we observed 2.5% (n = 49) and 2.2% (n = 18) prevalences of bronchiolitis hospitalization among premature infants who had ever and never received immunoprophylaxis, respectively. The small numbers observed might have been due to the significant improvement in premature infant medical care and outcomes over the past 20 years, with marked decreases in mortality, major changes in how care for premature infants is managed, advances in maternal immunization and nutrition, and changes in the pathophysiology of prematurity (28, 29) . All of these important changes have resulted in healthier preterm infants and in larger numbers of lower-gestational-age preterm infants who survive and whose vulnerability to RSV is likely different from that of 20 years ago.
Interestingly, we observed a large decrease in risk associated with receipt of RSV immunoprophylaxis in 949 low-risk infants who received immunoprophylaxis (aHR = 0.51, 95% CI: 0.30, 0.86). The median gestational age of these infants was 32 weeks (interquartile range, [32] [33] [34] [35] . Twenty-six percent of them (n = 243) had congenital heart disease or CLD. The fact that those infants were similar to eligible infants in many ways (Table 2) suggests either misclassification of high-risk eligibility groupings, with some high-risk infants being misclassified as low-risk ineligible infants, or the presence of infants who were very similar to high-risk infants but failed to meet specific eligibility criteria.
The AAP updated its RSV immunoprophylaxis guidelines in 2009 (12) and 2014 (5), which now results in eligibility for about half of the previously eligible infants. Our results indicated that the real-world receipt of RSV immunoprophylaxis tracks with these guidelines. The majority of the infants eligible under both older and current guidelines received at least 1 dose of immunoprophylaxis, while only about half of infants who would no longer be eligible under the up-to-date guidelines received at least 1 dose.
The strengths of this study include the large population, with detailed information on the timing of and adherence to RSV immunoprophylaxis. Previous observational studies on RSV immunoprophylaxis often included only subjects who were receiving, or had received, immunoprophylaxis as compared with subjects who did not receive immunoprophylaxis (30, 31) . There are significant problems with this approach, as pointed out above. Importantly, we demonstrated that administration of RSV immunoprophylaxis is itself an indication of increased risk of infection, and there is significant differential propensity for receipt, even within high-risk eligibility groups ( Table 2, Web Table 1 ) (32) . Thus, our approach to dealing with confounding by indication is critical to assessing real-world effectiveness. Another strength of this study was consideration of the protection window and the temporal relationship of immunoprophylaxis receipt and bronchiolitis visits to the RSV epidemic, something that has not been accounted for in prior observational studies. This is important, as it makes biological sense to account for presumed protection during periods following dosing, as well as higher and lower risks of infection depending on timing within the RSV season. Lastly, we assessed the association with RSV immunoprophylaxis using the unprotected periods of subjects who received at least 1 dose of immunoprophylaxis in order to minimize bias due to infants' differential risks of RSV infection and seasonal variation (Web Table 8 , Web Figure 5 ).
There are several important limitations of this work to consider. We lacked virological confirmation of the etiology of bronchiolitis. Bronchiolitis captured by International Classification of Diseases, Ninth Revision, codes might not be due to RSV; therefore, the effect of RSV immunoprophylaxis might have been diluted (33, 34) . To minimize the misclassification of bronchiolitis caused by viruses other than RSV, we limited the RSV season to November-March. Approximately 50%-70% of infant bronchiolitis hospitalizations occurring during the winter season were due to RSV (18, (35) (36) (37) . KPNC started to test for RSV using the polymerase chain reaction method in 2006. Among 544 bronchiolitis hospitalization episodes that infants experienced during NovemberMarch from 2006 to 2009, 64% (n = 350 episodes) tested RSVpositive (Kedir Turi, Vanderbilt University, unpublished data, 2018). Further, it is also possible that infants who receive RSV immunoprophylaxis are protected against viral agents other than RSV as a result of their protection against severe RSV infection (6). Therefore, the association detected in this study reflected the true real-world effectiveness of immunoprophylaxis. It must also be noted that the innate risk of RSV infection among study subjects was highly variable and that the decision to administer RSV immunoprophylaxis was influenced by known risk factors as well as subjective risk factors. This makes confounding by treatment indication (i.e., sicker or higher-risk infants being more likely to receive treatment) a particular problem in observational studies such as this one (32) . It is for this reason that our main analyses were restricted to patients who received at least 1 dose of immunoprophylaxis.
There were several additional limitations. Two types of immunoprophylaxis with different mechanisms, RSV immune globulin intravenous (licensed in 1996) and palivizumab (licensed in 1998), were available during the study period. We could not determine type of immunoprophylaxis or differentiate between the 2 types of immunoprophylaxis available during the study period. KPNC administrated palivizumab almost exclusively in 1998 and afterwards; therefore, our results were mainly driven by the effect of palivizumab (Web Tables 3 and 5) . Lastly, despite the fact that this is one of the largest population-based studies on the effectiveness of immunoprophylaxis to have been carried out to date, the study lacked statistical power for several high-risk subgroups. However, the groupings were based on the inclusion criteria from RCTs, and it may be that studies such as this can provide important data on groups who most benefit from this costly preventive intervention, particularly as numbers of RSV bronchiolitis events appear to be decreasing. In summary, in this real-world effectiveness study of RSV immunoprophylaxis, we have demonstrated that administration of RSV immunoprophylaxis was associated with a decreased risk of bronchiolitis hospitalization among high-risk infants, with infants with CLD, a group still recommended for receipt under the new 2014 AAP guidelines (5), experiencing the greatest risk reduction. Immunoprophylaxis was effective in reducing RSV-related morbidity during the 30 days following dosing regardless of prior receipt, supporting the importance of adherence to immunoprophylaxis therapy to provide protection in high-risk infants (38) (39) (40) . The additional protective effect of prior receipt of immunoprophylaxis suggests that a longer dosing schedule might be as effective as current monthly dosing recommendations. Lastly, approximately half of the infants previously eligible under the prior guidelines were no longer eligible under the updated 2014 guidelines for use of RSV immunoprophylaxis. However, the burden of disease and the effectiveness of RSV immunoprophylaxis were greatest in the population that is still covered under the latest guidelines. Until a vaccine for RSV is available, these up-to-date data on the effectiveness of RSV prophylaxis may aid in informing use of this preventive intervention among high-risk infants (41) .
